BR112017003800A2 - pyrazolothiazole compound and medicine - Google Patents
pyrazolothiazole compound and medicineInfo
- Publication number
- BR112017003800A2 BR112017003800A2 BR112017003800A BR112017003800A BR112017003800A2 BR 112017003800 A2 BR112017003800 A2 BR 112017003800A2 BR 112017003800 A BR112017003800 A BR 112017003800A BR 112017003800 A BR112017003800 A BR 112017003800A BR 112017003800 A2 BR112017003800 A2 BR 112017003800A2
- Authority
- BR
- Brazil
- Prior art keywords
- effect
- jak1
- present
- compounds
- inhibitory activity
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- -1 pyrazolothiazole compound Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 101150079478 jak1 gene Proteins 0.000 abstract 3
- VHHWHDFVZGPKRT-UHFFFAOYSA-N 5h-pyrazolo[3,4-d][1,3]thiazole Chemical class N1=NC2=NCSC2=C1 VHHWHDFVZGPKRT-UHFFFAOYSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000000592 Nasal Polyps Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000002327 eosinophilic effect Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 208000016366 nasal cavity polyp Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000009890 sinusitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
a invenção refere-se a um composto tendo um excepcional efeito inibidor de jak1. exemplos da presente invenção incluem os compostos de pirazolotiazol representado por fórmula geral [i], e sais farmaceuticamente aceitáveis do mesmo. os compostos da presente invenção têm atividade inibidora de jak1. dada esta atividade inibido-ra de jak1, os compostos da presente invenção da mesma forma têm efeito imunossupressor (contra, por exemplo, artrite reumatoide, doen-ça intestinal inflamatória, psoríase e vasculite), um efeito anti-inflamatório (contra, por exemplo, asma brônquica, doença pulmonar obstrutiva crônica, sinusite eosinofílica, pólipo nasal) um efeito antipro-liferativo, e similares.The invention relates to a compound having an exceptional inhibitory effect of jak1. Examples of the present invention include pyrazolothiazole compounds represented by general formula [i], and pharmaceutically acceptable salts thereof. The compounds of the present invention have jak1 inhibitory activity. Given this inhibitory activity of jak1, the compounds of the present invention likewise have immunosuppressive effect (against, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis, and vasculitis), an anti-inflammatory effect (against, for example, , bronchial asthma, chronic obstructive pulmonary disease, eosinophilic sinusitis, nasal polyp) an antiproliferative effect, and the like.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014177969 | 2014-09-02 | ||
| JP2014-177969 | 2014-09-02 | ||
| PCT/JP2015/074935 WO2016035814A1 (en) | 2014-09-02 | 2015-09-02 | Pyrazolothiazole compound and medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017003800A2 true BR112017003800A2 (en) | 2017-11-28 |
| BR112017003800B1 BR112017003800B1 (en) | 2022-09-13 |
Family
ID=55439874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017003800-5A BR112017003800B1 (en) | 2014-09-02 | 2015-09-02 | PYRAZOLOTHIAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION WITH JAK1 INHIBITOR EFFECT |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US9937176B2 (en) |
| EP (1) | EP3190116B1 (en) |
| JP (1) | JP6558372B2 (en) |
| KR (1) | KR102294330B1 (en) |
| CN (1) | CN107108653B (en) |
| AU (1) | AU2015312886B2 (en) |
| BR (1) | BR112017003800B1 (en) |
| CA (1) | CA2959721C (en) |
| CL (1) | CL2017000478A1 (en) |
| CO (1) | CO2017002982A2 (en) |
| CY (1) | CY1123320T1 (en) |
| DK (1) | DK3190116T3 (en) |
| ES (1) | ES2827243T3 (en) |
| HR (1) | HRP20201382T1 (en) |
| HU (1) | HUE050565T2 (en) |
| IL (1) | IL250729B (en) |
| LT (1) | LT3190116T (en) |
| MA (1) | MA40605B1 (en) |
| MX (1) | MX377926B (en) |
| MY (1) | MY181814A (en) |
| NZ (1) | NZ729494A (en) |
| PE (1) | PE20170668A1 (en) |
| PH (1) | PH12017500383B1 (en) |
| PL (1) | PL3190116T3 (en) |
| PT (1) | PT3190116T (en) |
| RS (1) | RS60798B1 (en) |
| RU (1) | RU2688660C2 (en) |
| SG (2) | SG10201901676UA (en) |
| SI (1) | SI3190116T1 (en) |
| SM (1) | SMT202000503T1 (en) |
| TW (1) | TWI679205B (en) |
| UA (1) | UA121869C2 (en) |
| WO (1) | WO2016035814A1 (en) |
| ZA (1) | ZA201701492B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI679205B (en) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | Pyrazolothiazole compounds and medicine |
| TWI712604B (en) | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | Crystal of compound with JAK inhibitory effect |
| US11167953B2 (en) | 2017-06-09 | 2021-11-09 | Mitsubishi Electric Corporation | Passenger conveyor |
| EP4081199A4 (en) * | 2019-12-23 | 2024-01-17 | SRI International | Lipoxygenase inhibitors |
| WO2025216268A1 (en) * | 2024-04-09 | 2025-10-16 | 国立研究開発法人国立循環器病研究センター | Prophylactic or therapeutic agent for severe pulmonary hypertension or connective tissue disease |
| JP7742516B1 (en) * | 2025-07-31 | 2025-09-19 | 日本新薬株式会社 | Treatment for eosinophilic granulomatosis with polyangiitis |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3600390A1 (en) | 1986-01-09 | 1987-07-16 | Hoechst Ag | DIARYLALKYL-SUBSTITUTED ALKYLAMINE, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND MEDICINAL PRODUCTS CONTAINING THE SAME |
| US5017212A (en) * | 1986-03-20 | 1991-05-21 | Takeda Chemical Industries, Ltd. | Sulfonylurea compounds and herbicidal use |
| US5082847A (en) | 1990-07-18 | 1992-01-21 | Syntex (U.S.A.) Inc. | Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility |
| GB0216383D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
| NZ546058A (en) | 2004-01-12 | 2010-09-30 | Ym Biosciences Australia Pty | Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors |
| CA2563963A1 (en) | 2004-04-28 | 2005-11-10 | Pfizer Inc. | 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor |
| ZA200802685B (en) * | 2005-09-30 | 2009-10-28 | Vertex Pharma | Deazapurines useful as inhibitors of janus kinases |
| CN103626742B (en) * | 2005-11-01 | 2017-04-26 | 塔格根公司 | Bi-aryl meta-pyrimidine inhibitors of kinases |
| CN102532133A (en) | 2006-01-17 | 2012-07-04 | 沃泰克斯药物股份有限公司 | Azaindoles useful as inhibitors of janus kinases |
| US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| RS52561B (en) * | 2008-04-15 | 2013-04-30 | Eisai R&D Management Co., Ltd. | COMPOUND 3-PHENYLPYRAZOLO [5,1-B] THIAZOL |
| JO3041B1 (en) | 2008-07-25 | 2016-09-05 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| US8524707B2 (en) * | 2008-12-19 | 2013-09-03 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazoles as protein kinase inhibitors |
| TWI462920B (en) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | Novel compound useful for the treatment of degenerative and inflammatory diseases |
| ES2461967T3 (en) | 2009-12-18 | 2014-05-21 | Pfizer Inc. | Pyrrolo [2,3-d] pyrimidine compounds |
| TW201124078A (en) | 2009-12-22 | 2011-07-16 | Du Pont | Fungicidal 2-(bicyclic aryloxy) carboxamides |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| JP2011136925A (en) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | Nitrogen-containing bicyclic compound |
| EP2523957A1 (en) | 2010-01-12 | 2012-11-21 | F. Hoffmann-La Roche AG | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| UY33213A (en) | 2010-02-18 | 2011-09-30 | Almirall Sa | PIRAZOL DERIVATIVES AS JAK INHIBITORS |
| JP2013532184A (en) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | N-sulfonylbenzamide derivatives useful as voltage-gated sodium channel inhibitors |
| WO2012022045A1 (en) | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| WO2012037132A1 (en) | 2010-09-14 | 2012-03-22 | Exelixis, Inc. | Phtalazine derivatives as jak1 inhibitors |
| EP2629777B1 (en) | 2010-10-22 | 2018-12-19 | Merck Sharp & Dohme Corp. | Bicyclic diamines as janus kinase inhibitors |
| WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
| WO2013025628A1 (en) * | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Janus kinase inhibitor compounds and methods |
| TWI679205B (en) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | Pyrazolothiazole compounds and medicine |
-
2015
- 2015-09-01 TW TW104128865A patent/TWI679205B/en active
- 2015-09-02 MX MX2017002488A patent/MX377926B/en unknown
- 2015-09-02 ES ES15838466T patent/ES2827243T3/en active Active
- 2015-09-02 US US15/505,767 patent/US9937176B2/en active Active
- 2015-09-02 WO PCT/JP2015/074935 patent/WO2016035814A1/en not_active Ceased
- 2015-09-02 RS RS20201081A patent/RS60798B1/en unknown
- 2015-09-02 CA CA2959721A patent/CA2959721C/en active Active
- 2015-09-02 PL PL15838466T patent/PL3190116T3/en unknown
- 2015-09-02 HR HRP20201382TT patent/HRP20201382T1/en unknown
- 2015-09-02 RU RU2017110535A patent/RU2688660C2/en active
- 2015-09-02 SG SG10201901676UA patent/SG10201901676UA/en unknown
- 2015-09-02 KR KR1020177008967A patent/KR102294330B1/en active Active
- 2015-09-02 MA MA40605A patent/MA40605B1/en unknown
- 2015-09-02 SG SG11201701447UA patent/SG11201701447UA/en unknown
- 2015-09-02 CN CN201580058944.7A patent/CN107108653B/en active Active
- 2015-09-02 HU HUE15838466A patent/HUE050565T2/en unknown
- 2015-09-02 LT LTEP15838466.9T patent/LT3190116T/en unknown
- 2015-09-02 SM SM20200503T patent/SMT202000503T1/en unknown
- 2015-09-02 SI SI201531340T patent/SI3190116T1/en unknown
- 2015-09-02 DK DK15838466.9T patent/DK3190116T3/en active
- 2015-09-02 EP EP15838466.9A patent/EP3190116B1/en active Active
- 2015-09-02 MY MYPI2017700677A patent/MY181814A/en unknown
- 2015-09-02 JP JP2016546669A patent/JP6558372B2/en active Active
- 2015-09-02 PE PE2017000370A patent/PE20170668A1/en unknown
- 2015-09-02 BR BR112017003800-5A patent/BR112017003800B1/en active IP Right Grant
- 2015-09-02 UA UAA201702990A patent/UA121869C2/en unknown
- 2015-09-02 PT PT158384669T patent/PT3190116T/en unknown
- 2015-09-02 AU AU2015312886A patent/AU2015312886B2/en active Active
- 2015-09-02 NZ NZ729494A patent/NZ729494A/en unknown
-
2017
- 2017-02-23 IL IL250729A patent/IL250729B/en active IP Right Grant
- 2017-02-28 ZA ZA2017/01492A patent/ZA201701492B/en unknown
- 2017-02-28 CL CL2017000478A patent/CL2017000478A1/en unknown
- 2017-03-01 PH PH12017500383A patent/PH12017500383B1/en unknown
- 2017-03-27 CO CONC2017/0002982A patent/CO2017002982A2/en unknown
- 2017-12-04 US US15/830,181 patent/US9999622B2/en active Active
-
2020
- 2020-09-04 CY CY20201100832T patent/CY1123320T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017003800A2 (en) | pyrazolothiazole compound and medicine | |
| BR112015032693A2 (en) | bromodomain inhibitors | |
| CY1124243T1 (en) | INHIBITING THE A1 TRANSIENT POTENTIAL RECEPTOR ION CHANNEL | |
| MX373786B (en) | PYRIMIDIN-2,4-DIAMINE DERIVATIVES FOR THE TREATMENT OF CANCER. | |
| TR201905814T4 (en) | Biprazole salt as a jack inhibitor. | |
| SA520411783B1 (en) | Condensed imidazole derivatives with tertiary hydroxy substitution as PI3K-gamma inhibitors | |
| UA118149C2 (en) | Jak inhibitor | |
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| GT201400085A (en) | ADRENOMEDULINE PROMOTE BASED ON POLYETHYLENE GLYCOL AND ITS USE | |
| BR112012023660B8 (en) | uses of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, for the treatment of cancer | |
| EA025158B9 (en) | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | |
| MY197564A (en) | Urat1 inhibitor and use thereof | |
| Baker et al. | Novel drug targets for asthma and COPD: lessons learned from in vitro and in vivo models | |
| BR112016007536A2 (en) | corresponding compounds, compositions and uses for the prevention and / or treatment of dyslipidemia | |
| CY1123607T1 (en) | A JAK-INHIBITING COMPOUND CRYSTAL | |
| PH12017502021A1 (en) | Cyclopropane carboxylic acid derivatives and pharmaceutical uses thereof | |
| BR112016029067A2 (en) | "compound, pharmaceutical composition, and methods for inhibiting the renal external medullary potassium channel, for causing diuresis, natriuresis or both and for treating one or more disorders". | |
| MX379437B (en) | SUBSTITUTED HYDRAZINE-BENZYL DERIVATIVES, AS INHIBITORS OF PPP1R15A AND PPP1R15B, AND THEIR USE FOR THE TREATMENT OF PROTEOSTASIS DISORDER. | |
| WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| LT3251675T (en) | PREVENTION OR TREATMENT OF URIC ACID (ACCUMULATION) OR Gout DISEASE | |
| CL2017000512A1 (en) | Treatment method and compositions comprising a double pi3k delta-gamma kinase inhibitor and a corticosteroid. | |
| TH1701001056A (en) | Pyrazolothiazole and its medicinal compounds include them. | |
| EP3645747A4 (en) | Methods for diagnosing inflammatory phenotypes of chronic obstructive pulmonary disease | |
| AU2017902450A0 (en) | Methods for diagnosing inflammatory phenotypes of chronic obstructive pulmonary disease | |
| TH174515A (en) | Heteroarylbutanoic acid derivatives Which are LTA4H inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/09/2015, OBSERVADAS AS CONDICOES LEGAIS |